Influenza and COVID‐19: What does co‐existence mean?
| Autor: | Arnold S. Monto, Jean-Michel Heraud, Thea Kølsen Fischer, Aeron C. Hurt, Yuelong Shu, Tawee Chotpitayasunondh, John S. Tam, Albert D. M. E. Osterhaus |
|---|---|
| Přispěvatelé: | Queen Sirikit National Institute of Child Health [Bangkok], Nordsjællands Hospital [Hillerød, Denmark], University of Southern Denmark (SDU), Institut Pasteur de Dakar, Réseau International des Instituts Pasteur (RIIP), Unité de Virologie [Antananarivo, Madagascar] (IPM), Institut Pasteur de Madagascar, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), F. Hoffmann-La Roche [Basel], University of Michigan [Ann Arbor], University of Michigan System, University of Veterinary Medicine [Hannover], Sun Yat-Sen University [Guangzhou] (SYSU), The Hong Kong Polytechnic University [Hong Kong] (POLYU) |
| Rok vydání: | 2020 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty Telemedicine Invited Review Article COVID-19/diagnosis Epidemiology Emerging technologies 030312 virology SARS‐CoV‐2 03 medical and health sciences antivirals COVID‐19 [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases Influenza Human Health care Pandemic clinical management medicine Humans Coinfection/epidemiology MESH: COVID-19 MESH: SARS-CoV-2 Influenza Human/diagnosis [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases 0303 health sciences MESH: Humans Coinfection SARS-CoV-2 business.industry MESH: Influenza Human Public health Public Health Environmental and Occupational Health COVID-19 [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biology medicine.disease MESH: Coinfection 3. Good health Vaccination Infectious Diseases Infectious disease (medical specialty) [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology surveillance [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie Business Medical emergency influenza Contact tracing |
| Zdroj: | Influenza and Other Respiratory Viruses Influenza and Other Respiratory Viruses, Wiley Open Access, 2020, 15 (3), pp.407-412. ⟨10.1111/irv.12824⟩ Chotpitayasunondh, T, Fischer, T K, Heraud, J M, Hurt, A C, Monto, A S, Osterhaus, A, Shu, Y & Tam, J S 2021, ' Influenza and COVID-19 : What does co-existence mean? ', Influenza and Other Respiratory Viruses, vol. 15, no. 3, pp. 407-412 . https://doi.org/10.1111/irv.12824 |
| ISSN: | 1750-2659 1750-2640 |
| DOI: | 10.1111/irv.12824 |
| Popis: | International audience; The COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2 continues to have a major impact on healthcare and social systems throughout the world. As the clinical and epidemiological features of COVID-19 have many parallels with influenza, it is important to ensure optimal management of both respiratory diseases as we anticipate their continued co-circulation. In particular, there is a need to ensure that effective surveillance and diagnostic capacities are in place to monitor these and other respiratory viruses, as this will underpin decisions on the appropriate clinical management of the respective diseases. As such, we propose a series of key recommendations for stakeholders, public health authorities, primary care physicians and surveillance bodies that will help mitigate the combined risks of concurrent influenza epidemics and the COVID-19 pandemic. We advocate the judicious use of influenza vaccines and antivirals, particularly among groups at high risk of complications, with healthcare workers also considered a priority for vaccination. It is likely that the increased use of emerging technologies such as telemedicine and contact tracing will permanently change our approach to managing infectious disease. The use of these technologies, alongside existing pharmaceutical strategies, will ensure that we achieve a holistic approach to the global public health measures needed to deal with the combined threat of influenza and COVID-19. Ensuring that this approach is optimal will be key as we move from a reactive pandemic response towards preparing for the long-term management of the remarkable clinical burden associated with these respiratory pathogens. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|